Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Shares Outstanding (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Shares Outstanding for 6 consecutive years, with $173.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 3.64% to $173.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $173.9 million through Dec 2025, up 3.64% year-over-year, with the annual reading at $173.9 million for FY2025, 3.64% up from the prior year.
  • Shares Outstanding for Q4 2025 was $173.9 million at Relay Therapeutics, up from $172.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $173.9 million in Q4 2025, with the low at $90.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $131.3 million, with a median of $122.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding tumbled 57.47% in 2021, then soared 35.5% in 2024.
  • Over 5 years, Shares Outstanding stood at $108.2 million in 2021, then grew by 11.92% to $121.1 million in 2022, then rose by 5.24% to $127.5 million in 2023, then soared by 31.61% to $167.8 million in 2024, then rose by 3.64% to $173.9 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $173.9 million, $172.6 million, and $171.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.